Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fibrogen Inc CS (NQ: FGEN )

0.3970 +0.0016 (+0.40%)
Streaming Delayed Price Updated: 1:48 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fibrogen Inc CS

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
FibroGen Stock Joins Rank Of Stocks With RS Ratings Over 90
On Tuesday, FibroGen stock saw a positive improvement to its Relative Strength Rating, rising to 94 from 90 a day earlier. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For June 2, 2023
Via Benzinga
FibroGen's Return on Invested Capital Overview
Via Benzinga
FibroGen's Anemia Candidate Fails In Myelodysplastic Syndrome Study
Via Benzinga
FibroGen Earnings Preview
Via Benzinga
FibroGen's Return On Capital Employed Insights
Via Benzinga
Analyst Ratings for FibroGen
Via Benzinga
Earnings Preview For FibroGen
Via Benzinga
B of A Securities Upgrades FibroGen: Here's What You Need To Know
Via Benzinga
Short Volatility Alert: FibroGen, Inc.
On Tuesday, shares of FibroGen, Inc. (NASDAQ: FGEN) experienced volatile short activity. After the activity, the stock price went down -4.38% to $12.87. The overall sentiment for FGEN has been... 
Via Benzinga
Why did Sarepta Therapeutics Stock Plummet?
SRPT stock fell 20% after the FDA changed course on their new DMD treatment approval. The stock remains strong with an encouraging outlook and a mod Buy rating. 
Via MarketBeat
Exposures Product Safety
FibroGen Shares Gain As Analyst Creates Bullish Pitch On Pulmonary Fibrosis Opportunity
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 26, 2023
Via Benzinga
Recap: FibroGen Q2 Earnings
  FibroGen (NASDAQ:FGEN) reported its Q2 earnings results on Monday, August 8, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For February 27, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million. 
Via Benzinga
Why ABVC BioPharma Shares Are Trading Higher By 129%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) shares surged 179.3% to $2.4585 after the company announced that it has entered into a license agreement for the development and commercialization... 
Via Benzinga
Perrigo, Tripadvisor, Lyft, And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded higher, with the Dow Jones gaining more than 400 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Via Benzinga
Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday
Gainers Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique Fabricating posted a Q3 loss of $0.90 per share after the closing bell on Tuesday. 
Via Benzinga
Why TaskUs Shares Are Trading Higher By 37%? Here Are 77 Stocks Moving In Tuesday's Mid-Day Session
Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares jumped 39.4% to $1.4529 after the company announced a payment assignment from the Centers for Medicare & Medicaid Services for the ProSense breast... 
Via Benzinga
FibroGen Earnings Preview
FibroGen (NASDAQ:FGEN) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here's what investors need to know before the announcement. Analysts estimate that FibroGen will report... 
Via Benzinga
7 Unknown Biotech Stocks That Could Rocket in 2023
Unknown biotech stocks that are poised for a big rally in 2023. Emerging biotech companies with a promising clinical pipeline. 
Via InvestorPlace
Recap Of Friday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
FibroGen Concludes Dosing In Late-Stage Blood Cell Disorder Study, Sees Top-line Data In H1 2023
FibroGen, Inc. (NASDAQ: FGEN) has completed patient enrollment for MATTERHORN, a Phase 3 clinical study of roxadustat for treatment of anemia in patients with lower risk transfusion-dependent... 
Via Benzinga
FIBROGEN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Provides Update of its Investigation of the Officers and Directors of FibroGen, Inc. - FGEN
From Kahn Swick & Foti, LLC
Via Business Wire
Preview: FibroGen's Earnings
FibroGen (NASDAQ:FGEN) is set to give its latest quarterly earnings report on Monday, 2022-08-08. Here's what investors need to know before the announcement. Analysts estimate that FibroGen will report... 
Via Benzinga
FIBROGEN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Provides Update of its Investigation of the Officers and Directors of FibroGen, Inc. - FGEN
From Kahn Swick & Foti, LLC
Via Business Wire
Akebia Therapeutics (AKBA) Stock Soars 18% Despite Lack of News
AKBA stock is up big, but the lack of news is concerning considering that Akebia Therapeutics already faces a regulatory setback. 
Via InvestorPlace
FibroGen, Inc. (NASDAQ:FGEN) Investor Alert: Investigation over Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 06/24/2022 -- An investigation was announced for current long-term investors in shares of FibroGen, Inc. (NASDAQ:FGEN) over potential breaches of fiduciary duties by... 
Via SBWire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.